by Desiree Cobb-Olori | May 23, 2025
In recognition of Huntington’s Disease (HD) Awareness Month, PsychoGenics is proud to support your HD research needs. With decades of experience in HD research, we offer three, fully characterized, mouse models of HD for assessing potential therapeutics: the zQ175...
by Desiree Cobb-Olori | Mar 28, 2025
C. Torturo and S. Ramboz Over the course of the past 20 years, CHDI and PsychoGenics have worked closely together on characterizing mouse models of Huntington’s disease. Primarily, the 120 CAG R6/2 model, the B6.Cg-Tg(HDexon1)61Gpb/J mouse line, or R6/1 model, and the...
by Desiree Cobb-Olori | Feb 19, 2025
Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disease caused by a high number of trinucleotide CAG repeats in the Huntingtin (Htt) gene. HD is classically associated with psychomotor symptoms including dyskinesia and dystonia,...
by Desiree Cobb-Olori | Feb 6, 2025
NF-L is a validated biomarker for assessing disease progression, intensity, and treatment response across a wide range of neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis...
by susan.forootan | Aug 6, 2024
The B6.Cg-Tg(HD exon1)61Gpb/J mouse line, or R6/1, is a Huntington’s disease model that carries the human huntingtin gene’s 5’ end (116-120 CAG repeats). Similar to the R6/2 mice, these mice motor deficits, seizures, reduced body weight, and muscle mass, however,...
